Drug Profile
Docetaxel liposomal - Plus Therapeutics
Alternative Names: ATI-1123; AZD 1123; CAN-001; DocePLUSLatest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator Azaya Therapeutics
- Developer Azaya Therapeutics; Plus Therapeutics
- Class Antineoplastics; Radiopharmaceutical diagnostics; Small molecules; Taxanes
- Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Small cell lung cancer
- No development reported Solid tumours
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV, Infusion)
- 28 Apr 2021 Plus Therapeutics has patent protection for docetaxel liposomal (DocePLUS) in the US
- 28 Apr 2021 Phase-I clinical trials in Small cell lung cancer in USA (IV) before April 2021 (Plus Therapeutics pipeline, April 2021)